Tamtam Try Tamtam free
Henry Schein logo

Henry Schein account plan

global healthcare products services

At a glance

Henry Schein distributes health care products and software to dental and medical practices, with $13,184 million FY2025 sales and about 25,000 employees.

Henry Schein (Nasdaq: HSIC), headquartered in Melville, New York, provides health care products, specialty products, software and services primarily to office-based dental and medical practitioners. It serves more than one million customers from 38 distribution centers and 17 manufacturing facilities, with operations or affiliates in 34 countries and territories. FY2025 net sales were $13,184 million (+4.0%), operating income $653 million and net income attributable to Henry Schein $398 million. It employs about 25,000 people, and KKR invested $250 million in May 2025 under a strategic partnership.

Business units

Strategic priorities

Practice improvement platform
CEO Fred Lowery wants Henry Schein positioned less as a distributor and more as the practice improvement platform for its customers within three years.
Value creation programme
More than $200 million of operating income improvement, including a $125 million run rate by the end of 2026, through outsourcing of finance and customer service, centralised indirect procurement and data-driven pricing.
Higher-growth, higher-margin mix
Software, specialty products and own brands are projected at 50% of total operating income in 2026, with a goal of over 50% by 2027.
BOLD+1 strategy
The 2025-2027 plan builds software, specialty and services businesses, operationalises One Distribution, leverages One Schein and drives digital transformation.
AI in dental software
AI-enabled packages Ascend Pro and Ascend Accelerate cover clinical documentation, eligibility, claims and imaging, and an MCP layer will let practices query their data with AI agents.

Latest results

In Q3 2026 (quarter ended September 26, 2026) net sales rose 4.0% to $3,471 million, with internal growth of 3.1%. U.S. dental merchandise grew 8.6%, specialty products 6.1% and technology 5.2%, while medical grew only 1.1%. Gross margin rose to 31.8% from 30.7%, helped by a $28 million net benefit from tariff refunds, and diluted EPS was $1.06 (vs $0.84). Nine-month sales were $10,297 million (+5.6%). FY2026 guidance was raised to non-GAAP EPS of $5.50-$5.56 with sales growth of 4.5%-5.5%, then recast to $5.42-$5.48 on November 16, 2026 after excluding remeasurement gains.

Investments and deals

Acquisitions
2025 acquisitions across all three segments totalled $392 million of consideration; 2026 acquisitions in distribution and specialty products totalled $93 million, including a majority stake in S.I.N. 360.
Global outsourcing and shared services
A global outsourcing provider was selected for finance and customer service and should deliver more than half of the G&A savings; 2027 adds broader outsourcing, AI for productivity and new supply chain software.
Restructuring plan
The 2024 restructuring plan runs to end-2027, with charges of $105 million in 2025 and $63 million in the first nine months of 2026.
Share buybacks
$450 million repurchased year to date in 2026, with about $330 million of authorisation left.

Challenges and risks

Leadership transition
Stanley Bergman retired as CEO on March 1, 2026 and the CFO changed on November 4, 2026; the 10-Q flags these transitions as a risk.
Weak medical segment
Medical grew only 1.1% in Q3 2026 as point-of-care diagnostic tests and respiratory vaccines fell.
Tariffs and Medicaid cuts
Tariffs and trade policy remain a risk, and the One Big Beautiful Bill Act is expected to reduce Medicaid enrolment and funding.
Cybersecurity
The October 2023 incident disrupted North American and European distribution; cybersecurity stays a named risk.
Competition and rising debt
Competition from Patterson, Benco, McKesson, Medline and implant makers continues, and total debt rose to $3,524 million at September 26, 2026.

What leadership says

“Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives”

Fred Lowery, Chief Executive Officer · Q3 2026 earnings release, November 3, 2026

“Coming soon is the launch of an MCP layer that enables practices to query their own data with AI applications and agents.”

Fred Lowery, Chief Executive Officer · Q2 2026 earnings call, August 4, 2026

“We're seeing primarily volume, which I think in the past we've seen primarily price.”

Fred Lowery, Chief Executive Officer · Q3 2026 earnings call, November 3, 2026

“excited about the meaningful opportunities ahead to drive growth, expand margins and create long-term shareholder value.”

Emmanuel Caprais, incoming CFO · Q3 2026 earnings call, November 3, 2026

Where a supplier can help

Business process outsourcing and shared services
The value creation programme relies on outsourcing finance and customer service and building shared services, which opens doors for BPO, automation and change-management providers.
Indirect procurement and pricing tools
A new procurement office centralising indirect spend and data-driven pricing create demand for spend analytics and pricing software.
Supply chain software
New supply chain software to cut inventory is a stated 2027 initiative across 38 distribution centers.
AI and data partners for Henry Schein One
AI-enabled Dentrix Ascend packages and the MCP layer point to partnerships in clinical AI, voice documentation, claims automation and data infrastructure.
Cybersecurity
The 2023 incident and cybersecurity as a named risk make security services relevant across distribution and the software business.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Henry Schein?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Henry Schein

What does Henry Schein do?

Henry Schein distributes dental and medical supplies and equipment, makes dental implants and other specialty products, and sells dental practice software through Henry Schein One.

What is Henry Schein's revenue?

FY2025 net sales were $13,184 million, up 4.0%; nine-month 2026 sales were $10,297 million.

How many employees does Henry Schein have?

About 25,000, with operations or affiliates in 34 countries and territories.

Who is Henry Schein's CEO?

Frederick M. (Fred) Lowery became CEO on March 2, 2026, succeeding Stanley M. Bergman, who remains Chairman. Emmanuel Caprais became CFO on November 4, 2026.

What is Henry Schein's strategy?

Accelerate growth, simplify the business and add rigour in execution, aiming for more than $200 million of operating income improvement and a larger share of software, specialty and own-brand profits.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)